The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old-Taiwan's PPV vaccination program

Vaccine

Volumn 33, Issue 25, 2015, Pages 2897-2902

  Tsai, Ying Huang ^a,b   Hsieh, Meng Jer ^a,b   Chang, Chee Jen ^b   Wen, Yu Wen ^b   Hu, Han Chung ^a,b   Chao, Yen Nan ^c   Huang, Yhu Chering ^a   Yang, Cheng Ta ^a,b   Huang, Chung Chi ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CENTER FOR DISEASE CONTROL   (Taiwan)

Author keywords

Influenza vaccine; Invasive pneumococcal disease; Mortality; Pneumococcal polysaccharide vaccine; Pneumonia

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; VACCINE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC LUNG DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INFLUENZA VACCINATION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; RHEUMATIC DISEASE; SYSTEMIC DISEASE; TAIWAN; VACCINATION; VERY ELDERLY; ADULT; IMMUNOLOGY; MORTALITY; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; PREVENTIVE HEALTH SERVICE; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HOSPITALIZATION; HUMANS; IMMUNIZATION PROGRAMS; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; TAIWAN; VACCINATION; VACCINE POTENCY;

EID: 84930000420     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.04.068     Document Type: Article

References (30)

1. Medical Expenditure Panel Survey Total health services-median and mean expenses per person with expense and mean expenses by source of payment: United States, 2010 2010, Medical Expenditure Panel Survey, http://meps.ahrq.gov/mepsweb/data_stats/quick_tables.jsp.
2. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. N Engl J Med 1995, 333(24):1618-1624.
3. Wang H., Chen M., Xu Y., Sun H., Yang Q., Hu Y., et al. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010. Int J Antimicrob Agents 2011, 38:376-383.
4. Lauderdale T.L., Chang F.Y., Ben R.J., Yin H.C., Ni Y.H., Tsai J.W., et al. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med 2005, 99(9):1079-1086.
5. Centers for Disease Control and Prevention, USA Active bacterial core surveillance (ABCs) report, emerging infections program network, Streptococcus pneumoniae, 2009 2010, Centers for Disease Control and Prevention, USA, Available from: http://www.cdc.gov/abcs/reports-findings/survreports/spneu09.pdf.
6. Kellner J.D., Vanderkooi O.G., MacDonald J., Church D.L., Tyrrell G.J., Scheifele D.W. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009, 49:205-212.
7. Forrester H.L., Jahnigen D.W., Marc Laforce F. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987, 83(3):425-430.
8. Fedson D.S. Pneumococcal vaccination in older adults. N Engl J Med 2003, 349(7):712-714.
9. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991, 325(21):1453-1460.
10. Christenson B., Hedlund J., Lundbergh P., Ortqvist A., Christenson B., Hedlund J., et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004, 23:363-368.
11. Ochoa-Gondar O., Vila-Corcoles A., Rodriguez-Blanco T., Gomez-Bertomeu F., Figuerola-Massana E., Raga-Luria X., et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014, 58(7):909-917.
12. Anonymous Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997, 46(RR-08):1-24.
13. Cheng T.M. Taiwan's new national health insurance program: genesis and experience so far. Health Aff 2003, 22(3):61-76.
14. Guo S., Fraser M.W. Propensity score analysis, statistical methods and applications 2014, Sage Publication, CA. 2nd ed.
15. Austin P.C. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making 2009, 29(6):661-677.
16. Austin P.C. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg 2007, 134(5):1128-1135.
17. Fukushima W., Hayashi Y., Mizuno Y., Suzuki K., Kase T., Ohfuji S., et al. Selection bias in evaluating of influenza vaccine effectiveness: a lesson from an observational study of elderly nursing home residents. Vaccine 2008, 26:6466-6469.
18. Advisory Committee on Immunization Practices Recommended adult immunization schedule: United States. Ann Int Med 2012, 156(3):211-217.
19. European Centre for Disease Prevention and Control Use of pneumococcal polysaccharide vaccine for subjects over 65 years of age during and inter-pandemic period. Technical report of the scientific panel on vaccines and immunization 2007, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden, 18 January 2007; available from: http://ecdpc.europa.eu/documents/pdf/PPV23_18_Jan.pdf.
20. Moberley S., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013, 1(1). Art. No.: CD000422. 10.1002/14651858.CD000422.pub3.
21. Conaty S., Watson L., Dinnes J., Waugh N., Conaty S., Watson L., et al. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004, 22:3214-3224.
22. Fedson D.S., Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004, 22(8):927-946.
23. Vila-Corcoles A., Ochoa-Gondar O., Hospital I., Ansa X., Vilanova A. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006, 43(7):860-868.
24. Andrews N.J., Waight P.A., George R.C., Slack M.P.E., Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012, 30(48):6802-6808.
25. Chiang C-S., Chen Y-Y., Jiang S-F., Liu D-P., Kao P-H., Teng H-J., et al. National surveillance of invasive pneumococcal diseases in Taiwan, 2008-2012: differential temporal emergence of serotype 19A. Vaccine 2014, 32(27):3345-3349.
26. Nichol K.L., Baken L., Wuorenma J., Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999, 159(20):2437-2442.
27. Nichol K.L. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999, 17(Suppl. 1(0)):S91-S93.
28. Skull S.A., Andrews R.M., Byrnes G.B., Kelly H.A., Nolan T.M., Brown G.V., et al. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated. Vaccine 2007, 25(23):4631-4640.
29. Lackner T.E., Hamilton G.R., Hill J., Davey J.C., Guay D.R.P. Pneumococcal polysaccharide revaccination: immunoglobulin g seroconversion, persistence, and safety in frail, chronically ill older subjects. J Am Geriatr Soc 2003, 51(2):240-245.
30. Nelson J.C., Jackson M.L., Weiss N.S., Jackson L.A. New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniors. J Clin Epidemiol 2009, 62:687-694.